商业保险喉癌患者诊疗质量指标分析
基于MarketScan商业理赔数据,回顾性分析2010至2012年10,969例喉癌患者,评估基于指南的质量指标与并发症、费用的关联。初始治疗质量较高与30天死亡率、手术及内科并发症风险降低相关;部分质量指标与1年费用升高相关,而绩效指标质量较高与费用降低相关。高手术量医疗与较低1年费用相关。
要点
- 初始治疗质量较高与30天死亡率、手术及内科并发症风险降低相关。
- 诊断、初始治疗和监测质量较高与1年费用增加相关,绩效质量较高与费用降低相关。
- 高手术量医疗与较低1年费用相关,即使控制整体质量后仍显著。
核心结论
- 商业保险喉癌患者中,较高质量诊疗与较低的30天死亡率和并发症相关。
- 高手术量医疗与较低的1年费用相关,即使在控制质量后仍显著。
研究设计与样本
- 回顾性横断面分析,使用MarketScan商业理赔与就诊数据(Truven Health Analytics)。
- 纳入2010至2012年诊断为喉癌的10,969例患者,采用交叉表和多因素回归分析。
主要发现
- 初始治疗质量较高与30天死亡率较低相关(OR=0.21,95%CI 0.04-0.98)。
- 初始治疗质量较高与手术并发症较低相关(OR=0.39,95%CI 0.17-0.88)。
- 初始治疗质量较高与内科并发症较低相关(OR=0.68,95%CI 0.49-0.96)。
- 诊断质量较高与1年平均增量费用较高相关($20,126,95%CI $14,785-$25,466)。
- 初始治疗质量较高与1年平均增量费用较高相关($17,918,95%CI $10,481-$25,355)。
临床怎么用
- 关注初始治疗质量指标以降低30天死亡率和并发症。
- 考虑高手术量医疗以降低1年费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine associations between quality, complications, and costs in commercially insured patients treated for laryngeal cancer. STUDY DESIGN: Retrospective cross-sectional analysis of MarketScan Commercial Claim and Encounters data (Truven Health Analytics, Ann Arbor, Michigan, U.S.A.). METHODS: We evaluated 10,969 patients diagnosed with laryngeal cancer from 2010 to 2012 using cross-tabulations and multivariate regression. Using quality indicators derived from guidelines for recommended care, summary measures of quality were calculated for diagnosis, initial treatment, surveillance, treatment for recurrence, performance, and an overall summary measure of quality. RESULTS: Higher-quality care in the initial treatment period was associated with lower odds of 30-day mortality (odds ratio [OR] = 0.21, 95% confidence interval [CI] [0.04-0.98]), surgical complications (OR = 0.39 [0.17-0.88]), and medical complications (OR = 0.68 [0.49-0.96]). Mean incremental 1-year costs were higher for higher-quality diagnosis ($20,126 [$14,785-$25,466]), initial treatment ($17,918 [$10,481-$25,355]), and surveillance ($25,424 [$20,014-$30,834]) quality indicators, whereas costs were lower for higher-quality performance measures (-$45,723 [-$56,246--$35,199]) after controlling for all other variables. Higher-quality care was associated with significant differences in mean incremental costs for initial treatment in surgical patients ($-37,303 [-$68,832--$5,775]), and for the overall summary measure of quality in patients treated nonoperatively ($10,473 [$1,121-$19,825]). After controlling for the overall summary measure of quality, costs were significantly lower for patients receiving high-volume surgical care (mean -$18,953 [-$28,381--$9,426]). CONCLUSION: Higher-quality larynx cancer care in commercially insured patients was associated with lower 30-day mortality and morbidity. High-volume surgical care was associated with lower 1-year costs, even after controlling for quality. These data have implications for discussions of value and quality in an era of healthcare reform. LEVEL OF EVIDENCE: 2c. Laryngoscope, 127:2805-2812, 2017.
引用
- Britt CJ, Chang HY, Quon H, et al. Quality indicators of laryngeal cancer care in commercially insured patients. Laryngoscope. 2017. PMID: 28688188. doi:10.1002/lary.26728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。